China Healthcare Weekly (Jun.15) - Outlook of GLP-1 Market, WuXi Bio’s Placement, Keymed's Placement
GLP-1 market is approaching ceiling. WuXi Bio’s Placing price of HK$26.51-26.88 is expensive based on our forecast. Keymed's reasonable valuation...
540 Views
Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain
Wuxi Biologics Holdings is looking to raise up to US$288m by selling about 2% of Wuxi Biologics (2269 HK). This will be the 17th placement in the...
710 Views
Keymed Bioscience Placement - Track Record Isn’t Great but Recent Performance Has Been Better
Keymed Biosciences (2162 HK), along with its controlling shareholder, is looking to raise around US$112m to fund its R&D requirements.
418 Views
Xtalpi US$860m IPO Lockup Expiry - Last of the Lockup Release with Nearly All Shares in CCASS Now
XtalPi Holdings (2228 HK) was listed in Hong Kong on 13th Jun 2024 after raising US$126m. Its one-year lockup will expire soon.
751 Views
Pre-IPO Medtide (PHIP Updates) - Some Points Worth the Attention
​GLP-1 sales growth is at a turning point with market size potentially lower than expected, impacting growth outlook for peptide CXOs like Medtide....
389 Views